Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Filipits, M.
Right arrow Articles by Pirker, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Filipits, M.
Right arrow Articles by Pirker, R.
Clinical Cancer Research Vol. 6, 3417-3423, September 2000
© 2000 American Association for Cancer Research

Advances in Brief

Clinical Relevance of the Lung Resistance Protein in Diffuse Large B-Cell Lymphomas1

Martin Filipits, Ulrich Jaeger, Ingrid Simonitsch, Claudia Chizzali-Bonfadin, Harald Heinzl and Robert Pirker2

Division of Oncology [M. F., R. P.] and Division of Hematology and Hemostaseology [U. J., C. C-B.], Department of Internal Medicine I; Institute of Clinical Pathology [I. S.]; and Department of Medical Computer Sciences [H. H.]; University of Vienna, A-1090 Vienna, Austria


   ABSTRACT
Top
 ABSTRACT
Introduction
 Patients and Methods
 Results
 Discussion
 REFERENCES
 
Drug resistance of non-Hodgkin’s lymphomas may involve mechanisms of the multidrug resistance phenotype including the lung resistance protein (LRP) and the multidrug resistance protein (MRP1). To determine the clinical relevance of these multidrug resistance factors in previously untreated diffuse large B-cell lymphomas (n = 48), we studied LRP and MRP1 expression in lymphoma cells and their impact on clinical outcome. LRP and MRP1 expression were immunohistochemically assessed by means of the monoclonal antibodies LRP-56 and MRPr1, respectively. LRP was positive in 23% and MRP1 in 44% of the samples. LRP expression was associated with higher tumor stage (P = 0.03), elevated serum lactate dehydrogenase levels (P = 0.01), and the International Prognostic Index (P = 0.0001). LRP-positive patients had a lower complete response rate to polychemotherapy than LRP-negative patients (18 versus 65%; P = 0.006). Patients with LRP expression had a shorter overall survival than those without LRP expression (median of 0.9 years versus median not reached; P = 0.001). MRP1 expression was independent of clinical and laboratory parameters and had no impact on the outcome of chemotherapy or survival of the patients. These data suggest that LRP expression but not MRP1 expression is an important mechanism of drug resistance associated with worse clinical outcome in previously untreated diffuse large B-cell lymphomas. Thus, the reversal of LRP-mediated drug resistance may improve clinical outcome in diffuse large B-cell lymphoma in the future.


   Introduction
Top
 ABSTRACT
 Introduction
Patients and Methods
 Results
 Discussion
 REFERENCES
 
DLBCL3 can be effectively treated with conventional polychemotherapy regimens with or without radiotherapy (1 , 2) . In addition, high-risk patients may benefit from either high-dose consolidation treatment with hematopoietic stem cell support after having achieved complete response from initial chemotherapy (3) or initial high-dose induction chemotherapy with stem cell support (4) . Despite these improvements, 40–50% of the patients are not cured by chemotherapy because of drug-resistant disease.

MDR is one important type of drug resistance that is clinically relevant in leukemias (5 , 6) and several solid tumors (7) . Different mechanisms can contribute to MDR; some of them have already been studied in non-Hodgkin’s lymphomas. MDR1/P-glycoprotein expression occurs with various frequencies in lymphomas and is associated with clinical drug resistance to various anticancer drugs including anthracyclines and Vinca alkaloids (7 , 8) . Clinical trials to overcome P-glycoprotein-mediated resistance in drug-refractory lymphoma by combining chemotherapy with resistance modifiers indicated that, at least in a subset of patients with drug-refractory lymphoma, modulation of P-glycoprotein function is feasible, which suggests that P-glycoprotein expression plays a role in the drug resistance of this disease (9, 10, 11) . MRP1, another important factor involved in MDR, is also expressed in lymphomas (12) , but its impact on clinical outcome remains to be determined. Alterations in apoptosis and cell cycle regulation are also involved in drug resistance of lymphomas (13, 14, 15, 16) . p53 mutations were associated with poor outcome of chemotherapy and shorter survival in aggressive B-cell lymphomas (13) and in relapsed or drug-refractory non-Hodgkin’s lymphomas (14) . The cyclin-dependent kinase inhibitor p27Kip1 has also been shown to be involved in drug resistance (17) , and lack of its expression is associated with shorter disease-free survival and overall survival in patients with DLBCL (16) .

LRP is another protein that is associated with MDR. It was first detected in a non-P-glycoprotein-multidrug-resistant lung cancer cell line (18) and has been shown to be the human major vault protein (19) . Vaults are complex ribonucleoprotein particles that, in addition to the major vault protein, also contain several minor vault proteins and a small RNA (20) . Vaults are located mainly in the cytoplasm and, to a smaller degree, also in the nuclear membrane. They are believed to mediate intracellular and, in particular, nucleocytoplasmic transport (20) . LRP expression of tumor cell lines is associated with resistance to doxorubicin, vincristine, carboplatin, cisplatin, and melphalan (21) . A recent report by Kitazono et al. (22) provides evidence that LRP expression is involved in resistance to doxorubicin, vincristine, etoposide, paclitaxel, and gramicidin D and that LRP is associated with the transport of doxorubicin from the nucleus to the cytoplasm. LRP is physiologically overexpressed in colon tissue, lung tissue, renal proximal tubules, adrenal cortex and macrophages, but its physiological function remains to be evaluated (23) .

Because LRP and MRP1 affect drugs commonly used in the treatment of DLBCL, expression of these proteins may affect response to chemotherapy and survival in DLBCL. To further address this possibility, we have studied LRP expression and MRP1 expression in lymphoma cells and their association with both response to chemotherapy and survival of the patients.


   Patients and Methods
Top
 ABSTRACT
 Introduction
 Patients and Methods
Results
 Discussion
 REFERENCES
 
Patients.
Forty-eight previously untreated patients (21 females, 27 males) with DLBCL, diagnosed between 1991 and 1999, were included in this study. All of the biopsy samples were diagnosed at the Institute of Clinical Pathology, University of Vienna, Vienna, Austria. Between 1991 and 1994, diagnosis was based on the criteria of the Kiel classification (24) . Later on, lymphomas were typed according to the criteria provided in the Revised European-American Lymphoma (REAL) classification (25, 26, 27) , and the former cases were reviewed and also classified according to REAL criteria. Lymphomas were subtyped using standard histological and immunohistological methods. Cases with antecedent low-grade B-cell lymphomas were not included in this study.

The clinical characteristics of the patients are summarized in Table 1Citation . All of the patients received polychemotherapy. Twenty-eight patients were treated with CHOP, 19 patients with ProMACE-CytaBOM, and 1 patient with CEP. Patients with stage I disease received 3–4 cycles of chemotherapy plus consecutive radiotherapy (1) . Patients with stage II-IV disease received 6 cycles of chemotherapy. Two of them with bulky disease who achieved a complete response were treated with additional radiotherapy after 6 cycles of chemotherapy. All of the patients were evaluable for response. Response to chemotherapy was assessed according to standard criteria (28) . Complete response was defined as the absence of clinical and radiological evidence of disease for a minimum of at least 2 months. Eight patients received additional autologous bone marrow transplantation. In these patients, response assessment was performed after chemotherapy but before the transplantation.


View this table:
[in this window]
[in a new window]
  		Table 1 LRP and characteristics of patients with DLBCL

 
Age, tumor stage, serum lactate dehydrogenase, performance status, and the number of extranodal sites of the disease were used to determine the International Prognostic Index (29) . For statistical analysis, patients were grouped into low-risk (International Prognostic Index, 0–1), intermediate-risk (International Prognostic Index, 2–3), and high-risk (International Prognostic Index, 4–5) patients.

Immunohistochemical Detection of LRP and MRP1.
Immunohistochemistry was performed on formalin-fixed, paraffin-embedded lymphoma specimens. Paraffin sections were mounted on poly-L-lysin-coated glass microslides.

Sections were deparaffinized and rehydrated by consecutive submersions in xylene (two changes, 10 min each), absolute ethanol (two changes, 5 min each), 70% ethanol (two changes, 5 min each), and distilled water (3 min). Endogenous peroxidase activity was blocked by incubation in 0.06% H2O2 for 10 min at room temperature, and slides were washed in PBS. The tissues were preincubated for 20 min in normal serum (normal goat serum 1:50; Dako, Glostrup, Denmark) prior to an incubation for 2 h with either the LRP-56 monoclonal antibody (Alexis, Läufelfingen, Switzerland) or the MRPr1 monoclonal antibody (Alexis). Antibody binding was detected by the avidin-biotin-peroxidase method. Bound peroxidase was developed with 3,3'-diaminobenzidine (Dako). The slides were counterstained with Mayer’s Hämalaun and mounted with Aquatex (Merck, Darmstadt, Germany). All of the washes were performed in PBS.

Negative controls were performed as described above but without the monoclonal antibody. In some cases, additional controls with an irrelevant isotype-specific antibody (IgG2b for LRP-56 and IgG2a for MRPr1) were done. There was no difference in staining between the irrelevant isotype-specific antibodies and the negative controls without any primary antibody. Normal human kidney tissue, which is known to overexpress LRP and MRP1 (23 , 30) , was used as positive control.

Staining of lymphoma cells was examined by two investigators (M. F. and I. S.) without prior knowledge of the clinical outcome of the patients. Specimens were scored for the percentage of lymphoma cells showing granular cytoplasmic staining in the case of LRP and cytoplasmic and/or membrane staining in the case of MRP1. Staining was compared with corresponding negative and positive controls.

Statistical Analysis.
Associations between LRP or MRP1and clinical as well as laboratory parameters were assessed by {chi}2 test, Fisher‘s exact test, or exact Mann-Whitney test. Survival probabilities were calculated with the product limit method according to Kaplan-Meier (31) . Overall survival time was defined as the period between the time of diagnosis and the time of death. Survival times of patients still alive or patients who underwent bone marrow transplantation were censored with the date of the last follow-up or transplantation, respectively. Differences between survival curves were analyzed by means of the log-rank test. Logistic regression models and Cox proportional hazards regression models were used to assess the independent effects of covariables on survival (32) . All of the Ps are results of two-sided tests. The SAS statistical software system (SAS Institute Inc., Cary, NC, 1990) was used for calculations.


   Results
Top
 ABSTRACT
 Introduction
 Patients and Methods
 Results
Discussion
 REFERENCES
 
LRP and MRP1 Expression in DLBCL at Diagnosis.
LRP expression of previously untreated patients was immunohistochemically determined by means of the monoclonal antibody LRP-56. LRP staining was detected as characteristic granular cytoplasmic staining and ranged from 0 to 60%. In the case of positive staining, at least 10% of the lymphoma cells were stained. LRP expression was scored positive if any of the lymphoma cells showed brown cytoplasmic staining. LRP was positive in 11 (23%) of 48 lymphoma specimens at diagnosis (Table 1)Citation .

MRP1 expression was determined by means of the MRPr1 antibody. MRP1 staining ranged from 0 to 30% of the lymphoma cells. Any brown staining of lymphoma cells either cytoplasmic or membranous was scored as positive expression; MRP1 expression was positive in 21 (44%) of 48 samples (Table 2)Citation .


View this table:
[in this window]
[in a new window]
  		Table 2 MRP1 and characteristics of patients with DLBCL

 
Correlation of LRP and MRP1 with Clinical and Laboratory Parameters.
Next, we addressed the question as to whether LRP or MRP1 expression correlated with clinical or laboratory parameters. The major clinical and laboratory findings of the patients are summarized in Table 1Citation . There was no significant association between LRP expression and age, sex, and ß2-microglobulin (Table 1)Citation . However, LRP expression was more frequently observed in patients with stage III and IV disease and in patients with elevated serum lactate dehydrogenase (>240 units/liter; Table 1Citation ). Whereas 24 of 25 low-risk patients (International Prognostic Index, 0–1) were LRP-negative, 6 of 18 intermediate-risk (International Prognostic Index, 2–3) and 4 of 5 high-risk patients (International Prognostic Index, 4–5) were LRP-positive (P = 0.0001; Table 1Citation ).

MRP1 expression was independent of age, sex, ß2-microglobulin, serum lactate dehydrogenase, and the International Prognostic Index (Table 2)Citation . In addition, no correlation between MRP1 and LRP expression was observed (data not shown).

LRP and MRP1 Expression and Response to Chemotherapy.
All of the 48 patients received polychemotherapy. The treatment protocols were equally distributed among LRP-negative and LRP-positive patients (Table 1)Citation . All of the patients were evaluable for response to chemotherapy. The complete response rate of the total study population was 54%. Partial responses and no responses were seen in 21 and 25% of the patients, respectively. The complete response rate was 65% for patients without LRP expression but only 18% for patients with LRP expression (P = 0.006; Table 3Citation ). Partial responses and no responses occurred in 8 (22%) and 5 (13%) of LRP-negative patients but in 2 (18%) and 7 (64%) of LRP-positive patients (data not shown). With regard to MRP1, the complete response rate was 56% for MRP1-negative patients and 52% for MRP1-positive patients (P = 0.8; Table 3Citation ). Tumor stage (P = 0.001), serum lactate dehydrogenase (P = 0.01) and the International Prognostic Index (0.0001) were also significantly associated with complete response (Table 3)Citation . Because LRP expression correlated with tumor stage, we performed another analysis that excluded patients with stage I disease. In this analysis, the complete response rate was 56% for patients without LRP expression and 20% for patients with LRP expression (P = 0.05; data not shown).


View this table:
[in this window]
[in a new window]
  		Table 3 Outcome of chemotherapy

LRP expression of lymphoma cells and other clinical or laboratory parameters were compared with the outcome of chemotherapy. Chemotherapy protocols are described in "Patients and Methods."

 
Next we performed a logistic regression analysis that included LRP and the International Prognostic Index. In the univariate analysis, the odds ratios for no complete response were 8.3 for LRP (P = 0.006) and 9.5 for the International Prognostic Index (P = 0.0001; Table 4Citation ). In the multivariate analysis, the odds ratios for no complete response were 2.3 for LRP (P = 0.4) and 7.6 for the International Prognostic Index (P = 0.004; Table 4Citation ).


View this table:
[in this window]
[in a new window]
  		Table 4 Logistic regression analysis of no complete response

For this analysis, the International Prognostic Index was grouped into low risk (0–1), intermediate risk (2–3), and high risk (4–5).

 
LRP and MRP1 Expression and Survival.
Overall survival was estimated according to Kaplan-Meier. Fifteen patients died (7 LRP-negative patients, 8 LRP-positive patients). Overall survival was significantly shorter in patients with LRP expression (Fig. 1)Citation . At a median follow-up of 2.1 years, median overall survival of all of the patients was not reached. Median overall survival was 0.9 years for LRP-positive patients and was not reached for LRP-negative patients (P = 0.001). With regard to MRP1, 8 MRP1-negative patients and 7 MRP1-positive patients died. Median overall survival was not different between patients with MRP1 expression and those without MRP1 expression (P = 0.9; Fig. 2Citation ). In patients with stage II-IV disease (n = 37), overall survival remained significantly shorter in LRP-positive patients than in LRP-negative patients (median 0.9 years versus median not reached; P = 0.03; data not shown).



View larger version (13K):
[in this window]
[in a new window]
  		Fig. 1. LRP and overall survival. LRP expression in lymphoma cells was determined by immunohistochemistry, and overall survival was estimated according to Kaplan-Meier in 48 patients. Survival data based on LRP expression are shown. Statistical comparison between survival curves was done by the log-rank test.

 


View larger version (14K):
[in this window]
[in a new window]
  		Fig. 2. MRP1 and overall survival. Overall survival was estimated according to Kaplan-Meier in 48 patients. Survival data based on MRP1 expression are shown. Statistical comparison between survival curves was done by the log-rank test.

 
In the univariate Cox regression analysis, the relative risk for death was 4.9 for LRP (P = 0.001) and 4.6 for the International Prognostic Index (P = 0.0001; Table 5Citation ). In the multivariate Cox regression analysis that included LRP and the International Prognostic Index, the relative risk for death was 1.4 for LRP (P = 0.6) and 4.0 for the International Prognostic Index (P = 0.005; Table 5Citation ).


View this table:
[in this window]
[in a new window]
  		Table 5 Cox regression analysis of overall survival

For this analysis, the International Prognostic Index was grouped into low risk (0–1), intermediate risk (2–3), and high risk (4–5).

 

   Discussion
Top
 ABSTRACT
 Introduction
 Patients and Methods
 Results
 Discussion
REFERENCES
 
In the present study, we have determined the expression of LRP and MRP1 in DLBCL and compared the expression with clinical and laboratory parameters of the patients. LRP was positive in 23% and MRP1 in 44% of newly diagnosed DLBCL. LRP expression was associated with poor response to chemotherapy and shorter overall survival, which suggests that LRP is a clinically relevant drug-resistance factor in DLBCL. A similar predictive and prognostic value of LRP expression has previously been reported for acute myeloid leukemia (33, 34, 35, 36) , acute lymphoblastic leukemia (37) , multiple myeloma (38 , 39) , and advanced ovarian cancer (40) .

LRP strongly correlated with the International Prognostic Index (Table 1)Citation . This could explain why LRP lost its statistical significance in the multivariate model. The lack of independent prognostic significance, however, does not mean that LRP is not causative for clinical drug resistance in DLBCL. It also has to be stressed that LRP, but not the factors of the International Prognostic Index, could be altered by therapeutic interventions in the future, thereby improving clinical outcome.

MRP1 expression had no impact on the outcome of chemotherapy or survival of the patients. Similar results have previously been reported in refractory lymphoma patients in which MRP expression has been determined by means of a quantitative PCR assay both before and after chemotherapy (12) . MRP1 levels were not different between the pre- and postchemotherapy groups, which suggests that MRP1 overexpression is not responsible for non-P-glycoprotein-mediated drug resistance in these patients. Previous studies in acute myeloid leukemia (35 , 36 , 41) , acute lymphoblastic leukemia (37) , and advanced ovarian cancer (40) also failed to demonstrate a predictive or prognostic significance of MRP1 expression.

MDR1/P-glycoprotein expression of lymphomas has been examined in previous studies. Immunohistochemical studies reported P-glycoprotein expression that ranged from 0 to 49% of samples from untreated patients (9 , 42, 43, 44, 45, 46, 47, 48, 49) . Conflicting results with regard to the clinical importance of MDR1/P-glycoprotein in lymphomas have been reported. MDR1/P-glycoprotein predicted for poor response to induction chemotherapy in two studies (44 , 47) but not in two other studies (45 , 46) . In pretreated lymphomas, MDR1/P-glycoprotein expression was increased because of induction or selection of P-glycoprotein expressing clones (9 , 48) .

Mutations or overexpression of the p53 gene have been described as predictors of poor response to chemotherapy and shorter survival of lymphoma patients (13, 14, 15) . In aggressive B-cell lymphomas, patients with p53 mutations had a lower complete response rate and a shorter overall survival as compared with patients with wild-type p53 (13) . A multivariate analysis that included p53 and factors of the International Prognostic Index demonstrated that mutant p53 was an independent predictive and prognostic factor (13) .

Overexpression of bcl-2 confers drug resistance in vitro by inhibiting apoptosis (50) . Although an association between bcl-2 and response to chemotherapy could not be demonstrated (14 , 51, 52, 53, 54) , bcl-2 expression correlated with a higher relapse-rate (52) , shorter disease-free survival (51 , 53 , 54) , and shorter overall survival (53) .

In conclusion, LRP expression is associated with poor response to chemotherapy and with shorter survival of the patients with DLBCL and, therefore, may be an important mechanism of drug resistance in this disease. Thus, the development of strategies to clinically overcome LRP-mediated drug resistance should be attempted and might improve clinical outcome in DLBCL in the future.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This study was supported by the Austrian "Fonds zur Förderung der wissenschaftlichen Forschung" (Project No. P12264-MED) and by a grant from the Interdisciplinary Cooperative Project "Molecular Medicine" from the Austrian Ministry of Science. Back

2 To whom requests for reprints should be addressed, at Division of Oncology, Department of Internal Medicine I, University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria. Phone: 43-1-40400-4429; Fax: 43-1-40400-4461; E-mail: robert.pirker{at}akh-wien.ac.at Back

3 The abbreviations used are: DLBCL, diffuse large B-cell lymphomas; MDR, multidrug resistance; MRP, MDR protein; LRP, lung resistance protein; CHOP, cyclophosphamide/doxorubicin/vincristine/prednisone; ProMACE-CytaBOM, prednisone/doxorubicin/cyclophosphamide/etoposide/cytarabine/bleomycin/vincristine/methotrexate/leucovorin; CEP, lomustine/etoposide/prednimustine. Back

Received 3/ 3/00; revised 6/28/00; accepted 7/ 3/00.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Patients and Methods
 Results
 Discussion
 REFERENCES
 

  1. Miller T. P., Dahlberg S., Cassady J. R., Adelstein D. J., Spier C. M., Grogan T. M., LeBlanc M., Carlin S., Chase E., Fisher R. I. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N. Engl. J. Med., 339: 21-26, 1998.[Abstract/Free Full Text]
  2. Fisher R. I., Gaynor E. R., Dahlberg S., Oken M. M., Grogan T. M., Mize E. M., Glick J. H., Coltman C. A., Miller T. P. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N. Engl. J. Med., 328: 1002-1006, 1993.[Abstract/Free Full Text]
  3. Haioun C., Lepage E., Gisselbrecht C., Bastion Y., Coiffier B., Brice P., Bosly A., Dupriez B., Nouvel C., Tilly H., Lederlin P., Biron P., Brière J., Gaulard P., Reyes F. , for the Groupe d’Etude des Lymphomes de l’Adulte. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin’s lymphoma: updated results of the prospective study LNH87-2. J. Clin. Oncol., 15: 1131-1137, 1997.[Abstract/Free Full Text]
  4. Gianni A. M., Bregni M., Siena S., Brambilla C., Di Nicola M., Lombardi F., Gandola L., Tarella C., Pileri A., Ravagnani F., Valagussa P., Bonadonna G. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N. Engl. J. Med., 336: 1290-1297, 1997.[Abstract/Free Full Text]
  5. Pirker R., Wallner J., Geissler K., Linkesch W., Haas O. A., Bettelheim P., Hopfner M., Scherrer R., Valent P., Havelec L., Ludwig H., Lechner K. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J. Natl. Cancer Inst., 83: 708-712, 1991.[Abstract/Free Full Text]
  6. Marie J-P., Zittoun R., Sikic B. I. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood, 78: 586-592, 1991.[Abstract/Free Full Text]
  7. Filipits M., Suchomel R. W., Zöchbauer S., Malayeri R., Pirker R. Clinical relevance of drug resistance genes in malignant diseases. Leukemia, 10(Suppl.3): S10-S17, 1996.
  8. Sandor V., Wilson W., Fojo T., Bates S. E. The role of MDR-1 in refractory lymphoma. Leuk. Lymphoma, 28: 23-31, 1997.[Medline]
  9. Miller T. P., Grogan T. M., Dalton W. S., Spier C. M., Scheper R. J., Salmon S. E. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J. Clin. Oncol., 9: 17-24, 1991.[Abstract/Free Full Text]
  10. Yahanda A. M., Adler K. M., Fisher G. A., Brophy N. A., Halsey J., Hardy R. I., Gosland M. P., Lum B. L., Sikic B. I. Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J. Clin. Oncol., 10: 1624-1634, 1992.[Abstract/Free Full Text]
  11. Wilson W. H., Bates S. E., Fojo A., Bryant G., Zhan Z., Regis J., Wittes R. E., Jaffe E. S., Steinberg S. M., Herdt J., Chabner B. A. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J. Clin. Oncol., 13: 1995-2004, 1995.[Abstract/Free Full Text]
  12. Zhan Z., Sandor V. A., Gamelin E., Regis J., Dickstein B., Wilson W., Fojo A. T., Bates S. E. Expression of the multidrug resistance-associated protein gene in refractory lymphoma: quantitation by a validated polymerase chain reaction assay. Blood, 89: 3795-3800, 1997.[Abstract/Free Full Text]
  13. Ichikawa A., Kinoshita T., Watanabe T., Kato H., Nagai H., Tsushita K., Saito H., Hotta T. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N. Engl. J. Med., 337: 529-534, 1997.[Abstract/Free Full Text]
  14. Wilson W. H., Teruya-Feldstein J., Fest T., Harris C., Steinberg S. M., Jaffe E. S., Raffeld M. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin’s lymphomas. Blood, 89: 601-609, 1997.[Abstract/Free Full Text]
  15. Møller M. B., Gerdes A-M., Skjødt K., Mortensen L. S., Pedersen N. T. Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell non-Hodgkin’s lymphoma. Clin. Cancer Res., 5: 1085-1091, 1999.[Abstract/Free Full Text]
  16. Sáez A., Sánchez E., Sánchez-Beato M., Cruz M. A., Chacón I., Muñoz E., Camacho F. I., Martínez-Montero J. C., Mollejo M., García J. F., Piris M. A. p27KIP1 is abnormally expressed in diffuse large B-cell lymphomas and is associated with an adverse clinical outcome. Br. J. Cancer, 80: 1427-1434, 1999.[CrossRef][Medline]
  17. St. Croix B., Flørenes V. A., Rak J. W., Flanagan M., Bhattacharya N., Slingerland J. M., Kerbel R. S. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat. Med., 2: 1204-1210, 1996.[CrossRef][Medline]
  18. Scheper R. J., Broxterman H. J., Scheffer G. L., Kaaijk P., Dalton W. S., van Heijningen T. H. M., van Kalken C. K., Slovak M. L., de Vries E. G. E., van der Valk P., Meijer C. J. L. M., Pinedo H. M. Overexpression of a Mr 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res., 53: 1475-1479, 1993.[Abstract/Free Full Text]
  19. Scheffer G. L., Wijngaard P. L. J., Flens M. J., Izquierdo M. A., Slovak M. L., Pinedo H. M., Meijer C. J. L. M., Clevers H. C., Scheper R. J. The drug resistance-related protein LRP is the human major vault protein. Nat. Med., 1: 578-582, 1995.[CrossRef][Medline]
  20. Kedersha N. L., Rome L. H. Isolation and characterization of a novel ribonucleoprotein particle: large structures contain a single species of small RNA. J. Cell Biol., 103: 699-709, 1986.[Abstract/Free Full Text]
  21. Izquierdo M. A., Shoemaker R. H., Flens M. J., Scheffer G. L., Wu L., Prather T. R., Scheper R. J. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int. J. Cancer, 65: 230-237, 1996.[CrossRef][Medline]
  22. Kitazono M., Sumizawa T., Takebayashi Y., Chen Z-S., Furukawa T., Nagayama S., Tani A., Takao S., Aikou T., Akiyama S-I. Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. J. Natl. Cancer Inst., 91: 1647-1653, 1999.[Abstract/Free Full Text]
  23. Izquierdo M. A., Scheffer G. L., Flens M. J., Giaccone G., Broxterman H. J., Meijer C. J. L. M., van der Valk P., Scheper R. J. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am. J. Pathol., 148: 877-887, 1996.[Abstract]
  24. The Non-Hodgkin’s Lymphoma Pathologic Classification Project. National Cancer Institute-sponsored study of classifications of non-Hodgkin’s lymphomas: summary and description of a working formulation for clinical usage. Cancer (Phila.)., 49: 2112–2135, 1982.
  25. Harris N. L., Jaffe E. S., Stein H., Banks P. M., Chan J. K. C., Cleary M. L., Delsol G., De Wolf-Peeters C., Falini B., Gatter K. C., Grogan T. M., Isaacson P. G., Knowles D. M., Mason D. Y., Muller-Hermelink H-K., Pileri S. A., Piris M. A., Ralfkiaer E., Warnke R. A. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Grou. p. Blood, 84: 1361-1392, 1994.[Free Full Text]
  26. Armitage J. O., Weisenburger D. D. for the Non-Hodgkin’s Lymphoma Classification Project. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. J. Clin. Oncol., 16: 2780-2795, 1998.[Abstract]
  27. Harris N. L., Jaffe E. S., Diebold J., Flandrin G., MullerHermelink H. K., Vardiman J., Lister T. A., Bloomfield C. D. World health organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting, Airlie House, VA, November 1997. J. Clin. Oncol., 17: 3835-3849, 1999.[Abstract/Free Full Text]
  28. Cheson B. D., Horning S. J., Coiffier B., Shipp M. A., Fisher R. I., Connors J. M., Lister T. A., Vose J., Grillo-López A., Hagenbeek A., Cabanillas F., Klippensten D., Hiddemann W., Castellino R., Harris N. L., Armitage J. O., Carter W., Hoppe R., Canellos G. P. Report of an International Workshop to standardize response criteria for non-Hodgkin’s lymphomas. J. Clin. Oncol., 17: 1244-1253, 1999.[Abstract/Free Full Text]
  29. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N. Engl. J. Med., 329: 987–994, 1993.
  30. Flens M. J., Zaman G. J. R., van der Valk P., Izquierdo M. A., Schroeijers A. B., Scheffer G. L., van der Groep P., de Haas M., Meijer C. J. L. M., Scheper R. J. Tissue distribution of the multidrug resistance protein. Am. J. Pathol., 148: 1237-1247, 1996.[Abstract]
  31. Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.[CrossRef]
  32. Cox D. R. Regression models and life tables. J. R. Stat. Soc., 34: 187-220, 1972.
  33. List A. F., Spier C. S., Grogan T. M., Johnson C., Roe D. J., Greer J. P., Wolff S. N., Broxterman H. J., Scheffer G. L., Scheper R. J., Dalton W. S. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood, 87: 2464-2469, 1996.[Abstract/Free Full Text]
  34. Filipits M., Pohl G., Stranzl T., Suchomel R. W., Scheper R. J., Jäger U., Geissler K., Lechner K., Pirker R. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood, 91: 1508-1513, 1998.[Abstract/Free Full Text]
  35. Borg A. G., Burgess R., Green L. M., Scheper R. J. , and Liu Yin, J. A. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival. Br. J. Haematol., 103: 1083-1091, 1998.[CrossRef][Medline]
  36. Filipits M., Stranzl T., Pohl G., Heinzl H., Jäger U., Geissler K., Fonatsch C., Haas O. A., Lechner K., Pirker R. Drug resistance factors in acute myeloid leukemia: a comparative analysis. Leukemia, 14: 68-76, 2000.[CrossRef][Medline]
  37. den Boer, M. L., Pieters, R., Kazemier, K. M., Rottier, M. M. A., Zwaan, C. M., Kaspers, G. J. L., Janka-Schaub, G., Henze, G., Creutzig, U., Scheper, R. J., and Veerman, A. J. P. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein. P-glycoprotein expression, and drug resistance in childhood leukemia. Blood, 91: 2092–2098, 1998.
  38. Raaijmakers H. G. P., Izquierdo M. A. I., Lokhorst H. M., de Leeuw C., Belien J. A. M., Bloem A. C., Dekker A. W., Scheper R. J., Sonneveld P. Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. Blood, 91: 1029-1036, 1998.[Abstract/Free Full Text]
  39. Filipits M., Drach J., Pohl G., Schuster J., Stranzl T., Ackermann J., Königsberg R., Kaufmann H., Gisslinger H., Huber H., Ludwig H., Pirker R. Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma. Clin. Cancer Res., 5: 2426-2430, 1999.[Abstract/Free Full Text]
  40. Izquierdo M. A., van der Zee A. G. J., Vermorken J. B., van der Valk P., Belien J. A. M., Giaccone G., Scheffer G. L., Flens M. J., Pinedo H. M., Kenemans P., Meijer C. J. L. M., de Vries E. G. E., Scheper R. J. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J. Natl. Cancer Inst., 87: 1230-1237, 1995.[Abstract/Free Full Text]
  41. Filipits M., Suchomel R. W., Zöchbauer S., Brunner R., Lechner K., Pirker R. Multidrug resistance-associated protein in acute myeloid leukemia: no impact on treatment outcome. Clin. Cancer Res., 3: 1419-1425, 1997.[Abstract]
  42. Schlaifer D., Laurent G., Chittal S., Tsuruo T., Soues S., Muller C., Charcosset J. Y., Alard C., Brousset P., Mazerrolles C., Delsol G. Immunohistochemical detection of multidrug resistance associated P-glycoprotein in tumour and stromal cells of human cancers. Br. J. Cancer, 62: 177-182, 1990.[Medline]
  43. Goldstein L. J., Galski H., Fojo A., Willingham M., Lai S-L., Gazdar A., Pirker R., Green A., Crist W., Brodeur G. M., Lieber M., Cossman J., Gottesman M. M., Pastan I. Expression of a multidrug resistance gene in human cancers. J. Natl. Cancer Inst., 81: 116-124, 1989.[Abstract/Free Full Text]
  44. Pileri S. A., Sabattini E., Falini B., Tazzari P. L., Gherlinzoni F., Michieli M. G., Damiani D., Zucchini L., Gobbi M., Tsuruo T., Baccarani M. Immunohistochemical detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas. Histopathology, 19: 131-140, 1991.[Medline]
  45. Niehans G. A., Jaszcz W., Brunetto V., Perri R. T., GajlPeczalska K., Wick M. R., Tsuruo T., Bloomfield C. D. Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse large cell and immunoblastic lymphomas. Cancer Res., 52: 3768-3775, 1992.[Abstract/Free Full Text]
  46. Rodriguez C., Commes T., Robert J., Rossi J. F. Expression of P-glycoprotein and anionic glutathione S-transferase genes in non-Hodgkin’s lymphoma. Leuk. Res., 17: 149-156, 1993.[CrossRef][Medline]
  47. Cheng A-L., Su I-J., Chen Y-C., Lee T-C., Wang C-H. Expression of P-glycoprotein and glutathione-S-transferase in recurrent lymphomas: the possible role of Epstein-Barr virus, immunophenotypes, and other predisposing factors. J. Clin. Oncol., 11: 109-115, 1993.[Abstract]
  48. Kang Y-K., Zhan Z., Regis J., Robey R., Meadows B., Dickstein B., Lee J. S., Otsuki T., Stetler-Stevenson M., Jaffe E. S., Solomon D., Wilson W. H., Fojo A., Bates S. E. Expression of mdr-1 in refractory lymphoma: quantitation by polymerase chain reaction and validation of the assay. Blood, 86: 1515-1524, 1995.[Abstract/Free Full Text]
  49. Drénou B., Lamy T., Amiot L., Fardel O., Caulet-Maugendre S., Sasportes M., Diebold J., Le Prisé P-Y., Fauchet R. CD3- CD56+ non-Hodgkin’s lymphomas with an aggressive behavior related to multidrug resistance. Blood, 89: 2966-2974, 1997.[Abstract/Free Full Text]
  50. Walton M. I., Whysong D., O’Connor P. M., Hockenbery D., Korsmeyer S. J., Kohn K. W. Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res., 53: 1853-1861, 1993.[Abstract/Free Full Text]
  51. Hermine O., Haioun C., Lepage E., d’Agay M. F., Briere J., Lavignac C., Fillet G., Salles G., Marolleau J-P., Diebold J., Reyes F., Gaulard P. , for the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin’s lymphoma. Blood, 87: 265-272, 1996.[Abstract/Free Full Text]
  52. Hill, M. E., MacLennan, K. A., Cunningham, D. C., Vaughan Hudson, B., Burke, M., Clarke, P., Di Stefona, F., Anderson, L., Vaughan Hudson, G., Mason, D., Selby, P., and Linch, D. C. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin’s lymphoma: a British National Lymphoma Investigation Study. Blood, 88: 1046–1051, 1996.
  53. Gascoyne R. D., Adomat S. A., Krajewski S., Krajewska M., Horsman D. E., Tolcher A. W., O’Reilly S. E., Hoskins P., Coldman A. J., Reed J. C., Connors J. M. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin’s lymphoma. Blood, 90: 244-251, 1997.[Abstract/Free Full Text]
  54. Sanchez E., Chacon I., Plaza M. M., Muñoz E., Cruz M. A., Martinez B., Lopez L., Martinez-Montero J. C., Orradre J. L., Saez A. I., Garcia J. F., Piris M. A. Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. J. Clin. Oncol., 16: 1931-1939, 1998.[Abstract]



This article has been cited by other articles:


Home page
 BloodHome page
C. Andreadis, P. A. Gimotty, P. Wahl, R. Hammond, J. Houldsworth, S. J. Schuster, and T. R. Rebbeck
Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma
Blood, April 15, 2007; 109(8): 3409 - 3416.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. Ovaa, B. M. Kessler, U. Rolen, P. J. Galardy, H. L. Ploegh, and M. G. Masucci
Activity-based ubiquitin-specific protease (USP) profiling of virus-infected and malignant human cells
PNAS, February 24, 2004; 101(8): 2253 - 2258.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Filipits, M.
Right arrow Articles by Pirker, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Filipits, M.
Right arrow Articles by Pirker, R.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online